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Abstract In order to assess the function of the different human
UDP-Gal:GlcNAc L4-galactosyltransferases, the cDNAs of two
of them, L4-GalT I and L4-GalT V, were expressed in the
baculovirus/insect cell expression system. The soluble recombi-
nant enzymes produced were purified from the medium and used
to determine their in vitro substrate specificities. The specific
activity of the recombinant L4-GalT V was more than 15 times
lower than that of L4-GalT I, using GlcNAcL-S-pNP as an
acceptor. Whereas L4-GalT I efficiently acts on all substrates
having a terminal L-linked GlcNAc, L4-GalT V appeared to be
far more restricted in acceptor usage. L4-GalT V acts with high
preference on acceptors that contain the GlcNAcL1C6GalNAc
structural element, as found in O-linked core 2-, 4- and 6-based
glycans, but not on substrates related to N-linked or blood group
I-active oligosaccharides. These results suggest that L4-GalT V
may function in the synthesis of lacNAc units on O-linked chains,
particularly in tissues which do not express L4-GalT I, such as
brain.
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is an enzyme that functions in the biosynthesis of complex-
type glycans by catalyzing the transfer of a galactose from
UDP-Gal to an acceptor substrate carrying a terminal
L-linked GlcNAc, resulting in the formation of a
GalL1C4GlcNAc (lacNAc) unit. In the lactating mammary
gland, L4-GalT interacts with K-lactalbumin to form the lac-
tose-synthase complex, which catalyzes the transfer of a gal-
actose to free glucose, yielding lactose [1^3]. Targeted inacti-
vation of the mouse L4-GalT I gene resulted in growth
retardation and early death of the mice, indicating that this
enzyme has an important function in embryonic development
and further growth of the animals [4,5]. The L4-GalT I-de¢-
cient mice were unable to produce lactose; they showed, how-
ever, a low residual GalT activity.
Recently, many sequences related to the L4-GalT gene ap-
peared in (EST) databases, indicating that the L4-GalT gene is
part of a gene family, also including the related Lymnaea
stagnalis L4-GlcNAcT gene that was cloned previously [6^9].
During the past years two chicken and three human homologs
were cloned, and all appeared to be true L4-GalTs [8,10^12],
which poses questions about their individual functions. In
addition, a glucosylceramide-speci¢c rat L4-GalT homolog
has been cloned [13], revealing that the L4-GalT gene family
contains enzymes with a wide variety of functions, including
an enzyme with a di¡erent UDP-sugar speci¢city [6] as well as
an enzyme using an acceptor deviant from those having a
terminal L-linked GlcNAc [13].
In a previous study [11] we described the cloning of a novel
human L4-GalT (GenBank accession number AB004550) that
we named L4-GalT II, but later was referred to as L4-GalT IV
[14], and L4-GalT V [12,15]. We showed in Northern blots
that L4-GalT V, as we name it now, is widely expressed in
human tissues [11]. Also L4-GalT I, L4-GalT II and L4-GalT
III are expressed in a variety of tissues [8,9]. This indicates
that in many tissues, and possibly in many cells, multiple L4-
GalTs are expressed resulting in a mixture of enzymes, which
makes it di⁄cult to assign observed L4-GalT activity to indi-
vidual enzymes. By a detailed study of the in vitro acceptor
substrate speci¢city of the di¡erent L4-GalTs we aimed to get
more insight into the in vivo function of the individual en-
zymes. In this study we investigate the acceptor substrate
speci¢city and kinetic parameters of L4-GalT V and compare
them with those of the well known L4-GalT I.
2. Materials and methods
2.1. Materials
The following persons kindly supplied us with compounds (num-
bers refer to the structures given in Table 1): 4 and 12, Dr. O. Hinds-
gaul (University of Alberta, Edmonton, Alta, Canada); 13, Dr. M.
Haraldsson (University of Stockholm, Sweden); 20, Dr. A. Veyrie'res
(Universite¤ Paris-Sud, France); 21, Dr. M. Messer (University of Sid-
ney, Australia). Compounds 1 and 5 were purchased from Sigma
Chemical Co. (St. Louis, MO, USA), 2, 3, 6-11 were obtained from
Toronto Research Chemicals (Toronto, Ont., Canada) and 18 from
Glycolipid Biochemicals (Birmingham, AL, USA). Oligosaccharides
14, 16 and 17 were derived from K1-acid glycoprotein by desialylation
(acid treatment), digestion with PNGase F, fractionation of the result-
ing oligosaccharides and digestion with jack bean L-galactosidase.
Glycopeptide as/ag-GP-F2 (15) was prepared from asialo-¢brinogen
by pronase digestion as described previously [16] followed by enzy-
matic degalactosylation. Glycolipid 19 was derived from paraglobo-
side, isolated from bovine erythrocyte ghosts [17], by enzymatic dega-
lactosylation. UDP-[3H]Gal (36 Ci/mmol) was purchased from New
England Nuclear (Boston, MA, USA). The sugar nucleotide donor
was diluted with unlabeled UDP-Gal (Sigma) to the desired speci¢c
radioactivity. All other chemicals were obtained from commercial
sources and were of the best quality available.
2.2. Plasmids and recombinant DNA techniques
Plasmids were propagated in the Escherichia coli K-12 strain XL-
Blue (Stratagene). Synthetic oligonucleotides were obtained from Iso-
gen Bioscience, Maarssen, The Netherlands. pVTBac-His was ob-
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tained from Dr. D.H. Joziasse, and pVTBac-HisT, which shows a
shift in reading frame in the multiple cloning site, from Dr. T. de
Vries [18].
Isolation of plasmid DNA was carried out by a modi¢cation of the
minilysate method, as described by [19], or with the QIAprep Spin
Miniprep kit (Qiagen). Dideoxynucleotide chain terminating sequenc-
ing reactions [20], were performed on double stranded plasmid DNA,
using the T7 sequencing kit (Pharmacia) and [K-35S]dATP (Amer-
sham). PCR was performed using Ampli-taq DNA polymerase (Per-
kin-Elmer) by 25 cycles (1 min 95‡C, 1 min 63‡C, 1 min 72‡C). Before
cloning, ampli¢ed fragments were puri¢ed according to the QIAquick
PCR puri¢cation protocol (Qiagen).
2.3. Construction of pVTBacHis-L4GalT expression plasmids
Human L4-GalT I cDNA [21] was partially digested with PstI and
EcoRI and a 1.2 kb PstI/EcoRI fragment, starting at base 176 of the
coding region, was ligated in PstI/EcoRI-digested pVTBac-His. A
5P truncated L4-GalT V cDNA fragment was obtained by PCR of
the complete cDNA [11] using the sense primer AAAGAGCTCC-
CAAGGCATTCTGATCCGG and the antisense primer ATT-
GAATTCAGTACTCGTTCACCTG. The PCR fragment was puri-
¢ed, digested with SacI and EcoRI, and ligated into SacI/EcoRI-
digested pVTBac-HisT. The resulting expression plasmids were se-
quenced.
2.4. Maintenance and infection of insect cells
Trichoplusia ni (‘BTI-TN-5B1-4’) and Spodoptera frugiperda pupal
ovary tissue (Sf9) insect cells were obtained from Invitrogen (San
Diego, CA, USA) and grown in Graces Insect Medium (Invitrogen)
supplemented with 10% fetal calf serum (Gibco-BRL), or High Five
Serum-Free medium (Invitrogen), both containing 50 Wg/ml gentami-
cin. Insect cells were grown as monolayers at 27‡C. The Baculo-gold
system (PharMingen) was used for construction of recombinant ba-
culovirus and Sf9 cells were used to produce recombinant virus. To
produce the recombinant enzymes, T. ni insect cells were seeded in
High-Five serum-Free medium in T75 £asks. Baculovirus was added
(multiplicity of infection of 6) when the cells showed 90^100% con-
£uence, and after 3^5 days the medium was collected. The medium
was centrifuged for 5 min at 1500 rpm in an Eppendorf centrifuge to
remove detached cells.
2.5. Puri¢cation of the recombinant proteins and immunoblotting
Medium of recombinant baculovirus-infected T. ni insect cells was
subjected to UDP-hexanolamine-Sepharose chromatography, essen-
tially as described previously [22]. The protein concentration of the
active eluted fractions was determined according to Peterson [23].
Proteins were separated by SDS-PAGE on a 10% polyacrylamide
gel, using the Mini-Protean II system (Bio-Rad). For Western blotting
[24] a monoclonal anti-polyhistidine antibody (Sigma Immunochem-
icals) was used as ¢rst antibody and goat anti-mouse peroxidase con-
jugate (TAGO Immunodiagnostic Reagents) as the second antibody.
2.6. Galactosyltransferase assays and kinetic parameters
GalT assays were performed for 60^120 min at 37‡C essentially as
described in [25] in a 50 Wl reaction mixture containing 5 Wmol sodium
cacodylate bu¡er pH 7.0, 25 nmol UDP-[3H]Gal (1 Ci/mol), 1 Wmol
MnCl2, 0.2 Wmol ATP, 0.25 Wl Triton X-100, 15 Wl enzyme prepara-
tion and 50 nmol p-nitrophenyl-N-acetyl-1-thio-L-D-glucosaminide
(GlcNAcL-S-pNP) or acceptor substrate as indicated. Control assays
lacking the acceptor substrate were carried out to correct for incor-
poration into endogenous acceptors. When mono- or oligosaccharides
were used as acceptor, the labeled product was separated from unin-
corporated label by chromatography on a 1 ml column of Dowex
1-X8 (Cl3 form) [26]. When pNP substrates were used as the acceptor,
the product was isolated using Sep-Pak C-18 cartridges (Waters) [27].
Kinetic parameters (Km and V) were estimated from Eadie-Hofstee
plots (acceptor substrate concentrations varied from 0.03 to 5 mM
(100 mM for GlcNAc)).
3. Results
3.1. Expression of soluble L4-GalT I and L4-GalT V cDNA in
insect cells
To obtain expression of human L4-GalT I and L4-GalT V
in insect cells, 5P truncated cDNA fragments encoding the
putative stem region and catalytic domain of these L4-GalTs
were inserted into baculovirus expression vectors downstream
of the polyhedrin promoter, the cleavable mellitin signal se-
quence and a poly-histidine (His6) tag. Expression of the re-
combinant baculoviruses in T. ni insect cells resulted in the
secretion of soluble enzymes, carrying an amino-terminal
poly-His6 tag. No L4-GalT activity could be detected in the
serum-free growth medium of insect cells infected with an
unrelated recombinant baculovirus. The recombinant human
L4-GalTs were puri¢ed from the medium. Western blotting
with a His6-speci¢c monoclonal antibody revealed that similar
amounts of protein were produced and puri¢ed for both re-
combinant enzymes (Fig. 1). The speci¢c activity of the puri-
¢ed L4-GalT I (220 mU/mg protein), however, appeared to be
more than 15 times higher than that of puri¢ed L4-GalT V
(13.3 mU/mg protein).
3.2. Acceptor speci¢city of the recombinant enzymes
The acceptor speci¢city of human L4-GalT V was com-
pared with that of the well known human L4-GalT I (Table
1). Whereas all substrates terminating with a terminal L-linked
GlcNAc were e⁄cient acceptors for L4-GalT I, L4-GalT V
appeared to be very restricted in its acceptor speci¢city.
GlcNAcL-S-pNP, and oligosaccharides representing O-linked
structures (acceptor substrates 9^11, Table 1) were good ac-
ceptor substrates for this enzyme. A hydrophobic aglycone
generally improved the acceptor properties of the oligosac-
charides. Optimal activity was found with acceptor substrates
carrying a terminal GlcNAc L1C6 linked to an K-GalNAc
residue (substrates 10 and 11). Substrates representing N-gly-
cans (12^17) were all poor acceptors, regardless of the pres-
ence of a hydrophobic aglycone (substrate 12) or the GlcNAc
linkage type. Also two acceptors related to blood group I-
active structures (20 and 21) showed relatively low acceptor
properties. Neither L4-GalT V nor L4-GalT I was active with
the substrate glucosylceramide. In contrast to our previous
results [11], the acceptor lacto-N-triaosylceramide (19) showed
a low but distinct activity. Essentially no L4-GalT V activity
Fig. 1. Western blot analysis of L4-GalT I and L4-GalT V produced
in High Five cells. The proteins of UDP-hexanolamine-Sepharose-
puri¢ed medium of High-Five cells producing L4-GalT I or
L4-GalT V (both 5.5 Wg) were separated on SDS-PAGE. Proteins
were transferred to nitrocellulose by Western blotting, and stained
by an anti-polyHis antibody.
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was found with monosaccharides other than GlcNAc, or an
acceptor with a GlcNAc residue in K-anomeric con¢guration.
3.3. Interaction of L4-GalT V with K-lactalbumin
In the mammary gland of mammals, L4-GalT I interacts
with K-lactalbumin (K-LA) to produce lactose. In Table 2 the
e¡ect of K-LA on the interaction of the soluble recombinant
L4-GalT V and L4-GalT I is shown using di¡erent acceptor
monosaccharides. Like L4-GalT I, human L4-GalT V is in-
hibited by K-LA in its action on GlcNAc. However, while the
¢rst enzyme is induced by K-LA to act on Glc to yield lactose,
L4-GalT V is indi¡erent in this regard and acts with low
activity on Glc regardless of whether or not K-LA is present.
In previous studies we had observed that K-LA is able,
although with low e⁄ciency, to induce L4-GalT I to act on
xylose, yielding the disaccharide GalL1C4Xyl (D.H. van den
Eijnden and R. Sta¡horst, unpublished results). By contrast,
L4-GalT V acts with very low e⁄ciency on Xyl in the absence
of K-LA, and not at all in the presence of this modi¢er pro-
tein.
3.4. Kinetic properties of the recombinant L4-GalTs
To substantiate the di¡erences in the observed acceptor
substrate speci¢city of human L4-GalT I and L4-GalT V,
the Km and V values with four di¡erent substrates were esti-
mated for both enzymes (Table 3). The a⁄nity of L4-GalT I
and L4-GalT V for GlcNAcL-S-pNP and the O-linked core 2
structure (11) appeared to be of the same order, whereas the V
values for L4-GalT V were much lower than those for L4-
GalT I. This resulted in kinetic e⁄ciencies for L4-GalT V
that are 30^40 times lower than those for L4-GalT I. The
kinetic e⁄ciency with which L4-GalT V acts on the N-linked
glycopeptide (15), however, appears to be much lower than
that found with GlcNAcL-S-pNP and the core 2 structure,
due to both a lower a⁄nity and lower V. The low kinetic
e⁄ciency of L4-GalT V found with GlcNAc is mainly due
to the low a⁄nity of the enzyme for this substrate.
4. Discussion
Acceptor speci¢city studies with the soluble forms of L4-
GalT V and L4-GalT I have shown that L4-GalT V displays a
much more restricted acceptor speci¢city than L4-GalT I. In
accord with previous studies, L4-GalT I acts on virtually any
substrate that carries a L-GlcNAc residue at its non-reducing
terminus at a relatively high intrinsic rate. By contrast, L4-
GalT V clearly prefers substrates that contain the
GlcNAcL1C6GalNAcK structural element suggesting that it
might function in the formation of lacNAc units at the L6-
Table 2
Activity of L4-GalT I and L4-GalT V on GlcNAc, Glc and Xyl in
the presence (+) or absence (3) of 10 mg K-lactalbumin (K-LA) per
ml
Acceptor (5 mM) Relative activity (%) of
L4-GalT I L4-GalT V
3K-LA +KLA 3K-LA +K-LA
GlcNAc 100 5 100 15
Glc 0.1 72 9 7
Xyl 6 0.1 6 10 6 1
100% corresponds to an activity of 313 and 2.8 mU/mg protein for
the enzymes, respectively.
Table 1
Acceptor speci¢city of recombinant L4-GalT I and L4-GalT V
100% corresponds to an activity of 220 and 13.3 U/mg protein for
the enzymes, respectively
aThe peptide portion of the glycopeptide consists for s 90% of Gly-
Glu-Asn and Glu-Asn in a ratio of 3:2.
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linked GlcNAc of core 2-, 4-, or 6-based O-linked glycans. A
role of L4-GalT V in the formation of lacNAc units on N-
glycans is less likely as this enzyme acts with low e⁄ciency on
all substrates that form part of N-linked glycans. Also accep-
tors that are related to blood group I-active substances (con-
taining the GlcNAcL1C6Gal element) are relatively poor
substrates. Recently a GlcNAc-6-O-sulfate-speci¢c L4-GalT
activity was demonstrated in human colorectal mucosa [28].
This activity, however, cannot be assigned to L4-GalT V as
this enzyme is not active with this substrate. It thus appears
that L4-GalT V is also not involved in the synthesis of 6-
sulfated structures such as 6-sulfo-sialyl Lewisx which has
been identi¢ed as a ligand for L-selectin [29].
The primary structure of L4-GalT V shows more resem-
blance to that of the glucosylceramide-speci¢c L4-GalT [13]
than to any other L4-GalT cloned so far. Yet the soluble L4-
GalT V tested in this study showed no activity with glucosyl-
ceramide. By contrast the full-length enzyme produced in in-
sect Sf9 cells [14] showed a low but distinct activity with this
glycolipid substrate (T. Sato and K. Furukawa, unpublished).
Similarly, truncated, soluble forms of K3/4-fucosyltransferases
show a diminished capability to act on glycolipids compared
to the full-length enzymes [30]. These results suggest that the
membrane spanning domain of glycosyltransferases somehow
is important for activity with glycolipids, perhaps by enabling
a close and properly oriented association between enzyme and
substrate in the membrane. On the other hand the soluble
form of L4-GalT V shows some activity with lacto-N-triaosyl-
ceramide (Lc3Cer), while the chimeric L4-GalT V-protein A
form of the enzyme was found to be inactive with this sub-
strate [11]. These data indicate that glycosyltransferase activ-
ities with glycolipid substrates may be highly sensitive to the
form (soluble, fusion protein, full-length) of the enzyme. In
addition to L4-GalT V and L4-GalT I (this study), the soluble
forms of L4-GalT III [8] and L4-GalT IV [12] also are capable
of acting on Lc3Cer, leaving the question unanswered whether
the synthesis of paragloboside (nLc4Cer) in vivo is catalyzed
by one or more L4-GalTs.
In contrast to L4-GalT I, L4-GalT V is not stimulated by K-
LA to act more e⁄ciently on Glc [11,14] but shows a low
intrinsic activity with this sugar. Its activity with GlcNAc,
however, is strongly inhibited at an K-LA concentration of
10 mg/ml. Furthermore, L4-GalT I and L4-GalT V di¡er
also in their relative activities with Xyl (the ancestor pentose
of Glc) in the absence and presence of K-LA, but the activities
of the other L4-GalTs with this acceptor have not been re-
ported. It may be expected that the L4-GalT functioning in
the synthesis of the GlcAL1C3GalL1C3GalL1C4XylL-O-
Ser core of proteoglycans (such as chondroitin sulfate and
heparin sulfate) [31] is also a member of the L4-galactosyl-
transferase family and that this enzyme displays a high spe-
ci¢city for xylosides. The properties of L4-GalT V do not meet
this criterion and therefore this enzyme appears not to have
this function.
Although the O-linked core 2 and the core 6 structures are
the most e⁄cient substrates for L4-GalT V, the kinetic e⁄-
ciency with which this enzyme acts on the core 2 structure is
about 30-fold lower than that shown by L4-GalT I. This im-
plies that it is not likely that L4-GalT V is the only L4-GalT
involved in the galactosylation of the core 2 oligosaccharide,
in particular because L4-GalT I is prominently present in most
tissues [9,11]. However, in brain L4-GalT I transcripts are
hardly detectable while L4-GalT V, L4-GalT III and L4-
GalT VI are well expressed in this tissue [8,9,11,12]. This
brain-speci¢c expression pattern of L4-GalTs might explain
the under-galactosylation of the N-linked glycans of certain
brain glycoproteins [32,33] as it is consistent with the poor
activity L4-GalT V shows with acceptors that are related to
Table 3
Apparent kinetic parameters of recombinant human L4-GalT I and L4-GalT V for several acceptor substrates
In the assays the concentrations of the acceptor substrates were varied over a range of 0.03^5.0 mM (1^100 mM for GlcNAc with L4-GalT V)
using otherwise standard incubation conditions.
FEBS 21927 26-4-99
I. van Die et al./FEBS Letters 450 (1999) 52^56 55
these glycans. In the absence of L4-GalT I, L4-GalT V might
indeed have a speci¢c function in the galactosylation of O-
linked structures.
While our work was in progress a study appeared favoring
a speci¢c role of L4-GalT IV rather than of L4-GalT I or L4-
GalT V in the synthesis of polylactosamine chains on O-
linked core 2 structures [15]. Although we did not test the
acceptor speci¢city of L4-GalT IV our results on L4-GalT I
and L4-GalT V clearly contradict the conclusion drawn by
these authors. Also we did not encounter the severe substrate
inhibition of L4-GalT I by the core 2 substrate which under-
lines the function of the latter enzyme in the galactosylation of
both N- and O-linked glycans.
In this study, we compared the kinetic properties and the in
vitro acceptor speci¢city of two human L4-GalTs. These data
are important to better understand their role in the synthesis
of lacNAc-based glycans. The in vivo function of these en-
zymes, however, will also depend on potential competition
with other L4-galactosyltransferases and L4-N-acetylgalacto-
saminyl transferases [34], subcellular localization, and pro-
tein-directed e¡ects.
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